Head-to-head evidence
Ipratropium vs PT001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline
Ipratropium
Developed by Boehringer Ingelheim
NCT06074185 · Phase 2 · completed
The study was not randomized or blinded and compared patients treated before and after implementation of the bundle rather than using a concurrent controlled trial; the intervention also included dexamethasone and a checklist, so the effect cannot be attributed to ipratropium alone. Although hospital admission is a clinical endpoint, the primary comparison was based on a small and internally inconsistent set of reported participants, with no reported significance analysis, so the result is unclear.
PT001
Developed by AstraZeneca
NCT03358147 · Phase 2/3 · completed
The study was randomized and quadruple-masked for the placebo comparison, included 1,077 participants, and used placebo and open-label active comparators. Its primary measure was a lung-function surrogate rather than a hard clinical outcome, and although the reported PT001 values were numerically higher than placebo, whether the prespecified primary comparison was statistically significant is not stated.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ipratropium's landscape · PT001's landscape